Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy

Anne Hagemann; Theodor W. May; Esther Nieder; Karin Witte-Bölt; Bernd Pohlmann-Eden; Christian E. Elger; Frithjof Tergau; Andreas Schulze-Bonhage; Hans Beatus Straub; Stephan Arnold; Christian Brandt

doi:10.1016/j.eplepsyres.2012.08.005

Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy

Anne Hagemann, Theodor W. May, Esther Nieder, Karin Witte-Bölt, Bernd Pohlmann-Eden, Christian E. Elger, Frithjof Tergau, Andreas Schulze-Bonhage, Hans Beatus Straub, Stephan Arnold, Christian Brandt

Medicine

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

15 Citas (Scopus)

Resumen

The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy. A prospective, open, investigator initiated multicenter study enrolled 140 patients in whom LEV was added to the existing antiepileptic medication. A total of 65 patients who benefited from the 16-week add-on treatment with LEV (≥50% seizure reduction) were converted to LEV monotherapy (16-week follow-up). In LEV responders, HRQoL, anxiety and depression improved after add-on of LEV. The subsequent conversion to LEV monotherapy did not lead to a significant change in HRQoL, anxiety and depression. However, comparing baseline with LEV monotherapy, the improvements remained significant for most dimensions of HRQoL and for anxiety and depression. Patients' ratings of efficacy of LEV were related with their HRQoL after the conversion to monotherapy. Add-on therapy of LEV improved HRQoL, anxiety and depression in LEV responders. Conversion to a LEV monotherapy did not inevitably improve HRQoL in LEV responders, but the positive effect was maintained in the majority of the patients. The effects were highly related to seizure reduction.

Idioma original	English
Páginas (desde-hasta)	140-150
Número de páginas	11
Publicación	Epilepsy Research
Volumen	104
N.º	1-2
DOI	https://doi.org/10.1016/j.eplepsyres.2012.08.005
Estado	Published - mar. 2013

Nota bibliográfica

Funding Information:
This investigator-initiated study was supported by UCB.

Funding Information:
CB, FT have received support from, and/or have served as a paid consultant for UCB, Pfizer, Eisai, Novartis, GSK, Janssen-Cilag, and Desitin. EN has received support from Sanofi Pasteur MSD. BP received research grants and honoraria from Desitin Germany, Eisai Canada, Pfizer, and UCB. CE received speaker honoraria from Desitin, Pfizer, UCB, GSK and grants from the Deutsche Forschungsgemeinschaft. AS has received support from and/or has received honoraria from Desitin, Eisai, GSK, Pfitzer, UCB. HS received research grants and honoraria from UCB, Eisai, Pfizer, Glaxo-Smith-Kline and Desitin. SA has participated in research projects of UCB/Schwarz BioSciences, Eisai, Novartis and Valeant. He also has served as a paid consultant for UCB and Janssen-Cilag, and received honorarium as a speaker for UCB, Janssen-Cilag and Eisai. TM has participated in research projects with unrestricted grants from Desitin, Eisai, GSK, Janssen-Cilag, Pfizer, Sanofi-Aventis and UCB. AH, KW have declared no conflicts of interest.

ASJC Scopus Subject Areas

Neurology
Clinical Neurology

Acceder al documento

10.1016/j.eplepsyres.2012.08.005

Otros archivos y enlaces

Citar esto

Hagemann, A., May, T. W., Nieder, E., Witte-Bölt, K., Pohlmann-Eden, B., Elger, C. E., Tergau, F., Schulze-Bonhage, A., Straub, H. B., Arnold, S., & Brandt, C. (2013). Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Research, 104(1-2), 140-150. https://doi.org/10.1016/j.eplepsyres.2012.08.005

Hagemann, A, May, TW, Nieder, E, Witte-Bölt, K, Pohlmann-Eden, B, Elger, CE, Tergau, F, Schulze-Bonhage, A, Straub, HB, Arnold, S & Brandt, C 2013, 'Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy', Epilepsy Research, vol. 104, n.º 1-2, pp. 140-150. https://doi.org/10.1016/j.eplepsyres.2012.08.005

@article{ffc35f0b0fc6451e8c138c45a3e6be69,

title = "Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy",

abstract = "The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy. A prospective, open, investigator initiated multicenter study enrolled 140 patients in whom LEV was added to the existing antiepileptic medication. A total of 65 patients who benefited from the 16-week add-on treatment with LEV (≥50% seizure reduction) were converted to LEV monotherapy (16-week follow-up). In LEV responders, HRQoL, anxiety and depression improved after add-on of LEV. The subsequent conversion to LEV monotherapy did not lead to a significant change in HRQoL, anxiety and depression. However, comparing baseline with LEV monotherapy, the improvements remained significant for most dimensions of HRQoL and for anxiety and depression. Patients' ratings of efficacy of LEV were related with their HRQoL after the conversion to monotherapy. Add-on therapy of LEV improved HRQoL, anxiety and depression in LEV responders. Conversion to a LEV monotherapy did not inevitably improve HRQoL in LEV responders, but the positive effect was maintained in the majority of the patients. The effects were highly related to seizure reduction.",

author = "Anne Hagemann and May, {Theodor W.} and Esther Nieder and Karin Witte-B{\"o}lt and Bernd Pohlmann-Eden and Elger, {Christian E.} and Frithjof Tergau and Andreas Schulze-Bonhage and Straub, {Hans Beatus} and Stephan Arnold and Christian Brandt",

note = "Funding Information: This investigator-initiated study was supported by UCB. Funding Information: CB, FT have received support from, and/or have served as a paid consultant for UCB, Pfizer, Eisai, Novartis, GSK, Janssen-Cilag, and Desitin. EN has received support from Sanofi Pasteur MSD. BP received research grants and honoraria from Desitin Germany, Eisai Canada, Pfizer, and UCB. CE received speaker honoraria from Desitin, Pfizer, UCB, GSK and grants from the Deutsche Forschungsgemeinschaft. AS has received support from and/or has received honoraria from Desitin, Eisai, GSK, Pfitzer, UCB. HS received research grants and honoraria from UCB, Eisai, Pfizer, Glaxo-Smith-Kline and Desitin. SA has participated in research projects of UCB/Schwarz BioSciences, Eisai, Novartis and Valeant. He also has served as a paid consultant for UCB and Janssen-Cilag, and received honorarium as a speaker for UCB, Janssen-Cilag and Eisai. TM has participated in research projects with unrestricted grants from Desitin, Eisai, GSK, Janssen-Cilag, Pfizer, Sanofi-Aventis and UCB. AH, KW have declared no conflicts of interest. ",

year = "2013",

month = mar,

doi = "10.1016/j.eplepsyres.2012.08.005",

language = "English",

volume = "104",

pages = "140--150",

journal = "Epilepsy Research",

issn = "0920-1211",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy

AU - Hagemann, Anne

AU - May, Theodor W.

AU - Nieder, Esther

AU - Witte-Bölt, Karin

AU - Pohlmann-Eden, Bernd

AU - Elger, Christian E.

AU - Tergau, Frithjof

AU - Schulze-Bonhage, Andreas

AU - Straub, Hans Beatus

AU - Arnold, Stephan

AU - Brandt, Christian

N1 - Funding Information: This investigator-initiated study was supported by UCB. Funding Information: CB, FT have received support from, and/or have served as a paid consultant for UCB, Pfizer, Eisai, Novartis, GSK, Janssen-Cilag, and Desitin. EN has received support from Sanofi Pasteur MSD. BP received research grants and honoraria from Desitin Germany, Eisai Canada, Pfizer, and UCB. CE received speaker honoraria from Desitin, Pfizer, UCB, GSK and grants from the Deutsche Forschungsgemeinschaft. AS has received support from and/or has received honoraria from Desitin, Eisai, GSK, Pfitzer, UCB. HS received research grants and honoraria from UCB, Eisai, Pfizer, Glaxo-Smith-Kline and Desitin. SA has participated in research projects of UCB/Schwarz BioSciences, Eisai, Novartis and Valeant. He also has served as a paid consultant for UCB and Janssen-Cilag, and received honorarium as a speaker for UCB, Janssen-Cilag and Eisai. TM has participated in research projects with unrestricted grants from Desitin, Eisai, GSK, Janssen-Cilag, Pfizer, Sanofi-Aventis and UCB. AH, KW have declared no conflicts of interest.

PY - 2013/3

Y1 - 2013/3

N2 - The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy. A prospective, open, investigator initiated multicenter study enrolled 140 patients in whom LEV was added to the existing antiepileptic medication. A total of 65 patients who benefited from the 16-week add-on treatment with LEV (≥50% seizure reduction) were converted to LEV monotherapy (16-week follow-up). In LEV responders, HRQoL, anxiety and depression improved after add-on of LEV. The subsequent conversion to LEV monotherapy did not lead to a significant change in HRQoL, anxiety and depression. However, comparing baseline with LEV monotherapy, the improvements remained significant for most dimensions of HRQoL and for anxiety and depression. Patients' ratings of efficacy of LEV were related with their HRQoL after the conversion to monotherapy. Add-on therapy of LEV improved HRQoL, anxiety and depression in LEV responders. Conversion to a LEV monotherapy did not inevitably improve HRQoL in LEV responders, but the positive effect was maintained in the majority of the patients. The effects were highly related to seizure reduction.

AB - The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy. A prospective, open, investigator initiated multicenter study enrolled 140 patients in whom LEV was added to the existing antiepileptic medication. A total of 65 patients who benefited from the 16-week add-on treatment with LEV (≥50% seizure reduction) were converted to LEV monotherapy (16-week follow-up). In LEV responders, HRQoL, anxiety and depression improved after add-on of LEV. The subsequent conversion to LEV monotherapy did not lead to a significant change in HRQoL, anxiety and depression. However, comparing baseline with LEV monotherapy, the improvements remained significant for most dimensions of HRQoL and for anxiety and depression. Patients' ratings of efficacy of LEV were related with their HRQoL after the conversion to monotherapy. Add-on therapy of LEV improved HRQoL, anxiety and depression in LEV responders. Conversion to a LEV monotherapy did not inevitably improve HRQoL in LEV responders, but the positive effect was maintained in the majority of the patients. The effects were highly related to seizure reduction.

UR - http://www.scopus.com/inward/record.url?scp=84875493996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875493996&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2012.08.005

DO - 10.1016/j.eplepsyres.2012.08.005

M3 - Article

C2 - 22959715

AN - SCOPUS:84875493996

SN - 0920-1211

VL - 104

SP - 140

EP - 150

JO - Epilepsy Research

JF - Epilepsy Research

IS - 1-2

ER -

Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto